Marco Perulli

Marco Perulli

Auto-generated profile, based on publicly available information

Marco Perulli

Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2021 in Movement Disorders Clinical Practice
Verified
Journal Article
Open access
PDF file
MPMarco Perulli
Marco Perulli
JPJosephine Poole
Josephine Poole
GLGiulia Di Lazzaro
Giulia Di Lazzaro
SDSasha D'Ambrosio
Sasha D'Ambrosio
KSKatri Silvennoinen
Katri Silvennoinen
SBSimona Balestrini
Simona Balestrini
Background: Although described as non‐progressive, alternating hemiplegia of childhood (AHC) can display a sudden deterioration, anecdotally reported mainly in childhood. Outcome in adulthood is uncertain.Objectives: Aim of this study is to describe the long‐term follow‐up of neurological function in adults with AHC.Methods: Seven adults with AHC were included in this retrospective single‐center study. Clinical history and previous investigation data were gathered from the review of medical records. Video‐documented neurological examination was performed at the last follow‐up visit in four out of the seven reported indivisuals.Results: Over a median follow‐up of 16 years, neurological outcome and trajectories were heterogeneous. All individuals showed new neurological signs or symptoms. Three experienced a serious irreversible neurological deterioration after prolonged quadriplegic episodes and/or status epilepticus in their second or third decade. One patient died at age 29.Conclusions: This video‐series suggests that AHC in adulthood is not stationary; larger cohorts are needed to identify genotype–phenotype correlations and clinically useful outcome predictors.

30 October 2025 in Epilepsia Open
Verified
Journal Article
Open access
MPMarco Perulli
Marco Perulli
MBMaddalena Bianchetti
Maddalena Bianchetti
GPGloria Pantalone
Gloria Pantalone
MQMichela Quintiliani
Michela Quintiliani
MGMaria Luigia Gambardella
Maria Luigia Gambardella
DBDomenica Immacolata Battaglia
Domenica Immacolata Battaglia
Objective: Highly purified cannabidiol (CBD) is approved as adjunctive therapy for seizures associated with Dravet syndrome (DS), Lennox–Gastaut syndrome (LGS), and tuberous sclerosis complex (TSC), although its role in other developmental and epileptic encephalopathies (DEEs) remains unexplored. The aim of this study was to assess the real‐world use, efficacy, and safety of CBD across a broad cohort of patients with DEEs, including off‐label indications. Methods: In this retrospective study, we evaluated 107 patients with DEEs treated with CBD for ≥3 months between 2020 and 2024. Data on seizure frequency, tolerability, retention, and non‐seizure outcomes were collected. Efficacy was defined as ≥50% or ≥75% seizure reduction. Statistical analyses explored predictors of response. Results: Patients had LGS (55.1%), DS (16.8%), TSC (8.4%), or other DEEs (19.6%), with a genetic etiology in 56.1%. At a median follow‐up of 20 months, 69% achieved ≥50% seizure reduction, and 21% achieved ≥75% reduction. Patients with LGS, TSC, and other DEEs showed higher efficacy and retention rates compared to DS. Genetic or unknown etiology was associated with better outcomes ( p = 0.011). Combination with valproate was associated with reduced efficacy ( p = 0.006), while combination with clobazam had no significant effect on efficacy nor safety. Non‐seizure improvements included increased alertness (56%), improved sleep quality (25%), and enhanced motor performance (14%). Adverse events occurred in 33.6%, mostly mild and transient; 9% discontinued due to side effects. Significances: This study confirms the effectiveness and good tolerability of CBD in a real‐world DEE population, including off‐label use. These findings support expanding CBD indications and underscore the need for prospective studies targeting both seizure and developmental outcomes. Plain language summary: This study looked at the use of cannabidiol (CBD), a cannabis‐based medicine, in 107 people with severe forms of epilepsy called developmental and epileptic encephalopathies (DEEs). With CBD add‐on, about two‐thirds of patients had fewer seizures, and some caregivers noticed improvements in alertness, sleep, or movement. Most patients tolerated the treatment well, but some experienced side effects, and a few had to stop taking it. While the results are promising, more research is needed to confirm how effective and safe CBD is for different types of DEEs, especially those not currently approved for treatment with CBD.

25 October 2025 in Epilepsia
Verified
Journal Article
Open access
SBSimona Balestrini
Simona Balestrini
IGIlaria Galli
Ilaria Galli
MRMaria Luisa Ricci
Maria Luisa Ricci
EPElena Parrini
Elena Parrini
DMDavide Mei
Davide Mei
RGRenzo Guerrini
Renzo Guerrini
Objective: To characterize the clinical, electroencephalographic, and genetic features of epilepsies featuring absence seizures within monogenic etiology, highlighting the diagnostic, treatment and prognostic implications. Methods: We conducted a retrospective, multicenter study including patients with monogenic epilepsies and electroencephalography (EEG)–documented absence seizures. We analyzed clinical data, electroclinical findings, neurodevelopmental outcomes, and treatment responses through standardized questionnaires and medical records. We classified genetic variants according to American College of Medical Genetics and Genomics (ACMG) guidelines and performed univariate and multivariate analyses to identify predictors of developmental outcomes. Results: We included 160 patients (111 female; median age at last follow‐up: 13 years) with absence seizures and confirmed pathogenic or likely pathogenic monogenic variants. The most frequently implicated genes were SLC2A1, SLC6A1, SYNGAP1 , CHD2, and SCN1A . Four genes— HESX1, NCKAP1, SON, STARD9 —had not been previously associated with absence seizures. In 35% of patients, absence seizures were the only seizure type and in 67% were the initial manifestation. Atypical features included irregular EEG discharges (56%) eyelid myoclonia (42%), and automatisms (33%). Early‐onset (before age 3) seizures occurred in 58% and was significantly associated with atypical features ( p < .03). Using existing International League Against Epilepsy (ILAE) epilepsy syndrome classification, 60% of patients could not be classified. Developmental delay occurred in 54%, intellectual disability in 65%, and other neurodevelopmental comorbidities in 49%. Predictors of poor developmental outcomes included early developmental delay, drug‐resistant epilepsy, and early absence onset. We found no difference in the prevalence of drug resistance across the various genetic etiologies. The most effective medications for absence seizures included valproate, ethosuximide, benzodiazepines, and lamotrigine. Disease‐specific therapies (e.g., ketogenic diet in SLC2A1 , stiripentol/fenfluramine in SCN1A) were effective in select cases. Significance: Absence seizures are a common manifestation of different monogenic epilepsies, often associated with early onset, atypical clinical and/or EEG features, developmental delay or drug resistance. Classification models should incorporate genetic data alongside electroclinical features, especially as next‐generation sequencing is increasingly used.

10 July 2024 in Epilepsy & Behavior
Verified
Journal Article
Open access
CPChiara Porto
Chiara Porto
MPMarco Perulli
Marco Perulli
CAChiara Arpaia
Chiara Arpaia
MVMarianna Villa
Marianna Villa
VAValentina Arcangeli
Valentina Arcangeli
DBDomenica Immacolata Battaglia
Domenica Immacolata Battaglia

10 November 2024 in NeuroImage: Clinical
Verified
Journal Article
Open access
GSGiulia Salvatici
Giulia Salvatici
GPGiovanni Pellegrino
Giovanni Pellegrino
MPMarco Perulli
Marco Perulli
ADAlberto Danieli
Alberto Danieli
PBPAOLO BONANNI
PAOLO BONANNI
GDGian Marco Duma
Gian Marco Duma
Epilepsy is one of the most diffused neurological disorders, affecting 50 million people worldwide. Around 30% of patients have drug-resistant epilepsy (DRE), defined as failure of at least two tolerated antiseizure medications (ASMs) to achieve sustained seizure freedom. Brain surgery is an effective therapeutic approach in this group, hinging on the accurate localization of the epileptic focus. The latter task is complex and requires multimodal investigation methods. Epilepsy is also a network disorder and represents one of the best application scenarios of methods leveraging brain functional organization at large scales. Connectivity analysis represents a promising tool for improving surgical assessment, enabling better identification of candidates who could benefit the most from epilepsy surgery. The scalp electroencephalography (EEG) is the most relevant tool to characterize epileptic activity. The EEG has benefited significantly from technological advancement across the last decades. Firstly, electrical source imaging (ESI) allows the reconstruction of electrical activity detected by EEG at the cortex level; secondly, functional connectivity (FC) allows the assessment of functional dependencies across brain areas. The EEG has therefore expanded potential applications in the localization and characterization of the epileptogenic network for surgical planning. As the translation of these methods in clinical practice is little discussed in the literature, we reviewed the investigations using EEG-derived FC. We showed that the FC-informed identification of the epileptic networks improves the localization precision in focal epilepsy. We discussed the heterogeneity in the results and methodology preventing prompt research-to-clinic translation. We finally provided practical suggestions for promoting the applicability of FC-based research in real clinical practice, looking for future research.

24 July 2023 in Epilepsy & Behavior
Verified
Journal Article
Closed access
MPMarco Perulli
Marco Perulli
ISIrene Scala
Irene Scala
RVRomina Venditti
Romina Venditti
AAAntonio Amadio
Antonio Amadio
MGMaria Luigia Gambardella
Maria Luigia Gambardella
DBDomenica Immacolata Battaglia
Domenica Immacolata Battaglia